KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Change in Cash (2016 - 2025)

Jazz Pharmaceuticals has reported Change in Cash over the past 16 years, most recently at $65.8 million for Q4 2025.

  • Quarterly results put Change in Cash at $65.8 million for Q4 2025, down 66.19% from a year ago — trailing twelve months through Dec 2025 was -$1.0 billion (down 212.62% YoY), and the annual figure for FY2025 was -$1.0 billion, down 212.62%.
  • Change in Cash for Q4 2025 was $65.8 million at Jazz Pharmaceuticals, down from $136.2 million in the prior quarter.
  • Over the last five years, Change in Cash for JAZZ hit a ceiling of $1.0 billion in Q1 2021 and a floor of -$1.2 billion in Q2 2021.
  • Median Change in Cash over the past 5 years was $59.6 million (2023), compared with a mean of $16.7 million.
  • Peak annual rise in Change in Cash hit 1518.11% in 2021, while the deepest fall reached 1527.71% in 2021.
  • Jazz Pharmaceuticals' Change in Cash stood at -$80.3 million in 2021, then skyrocketed by 152.44% to $42.1 million in 2022, then soared by 305.04% to $170.6 million in 2023, then rose by 14.13% to $194.7 million in 2024, then plummeted by 66.19% to $65.8 million in 2025.
  • The last three reported values for Change in Cash were $65.8 million (Q4 2025), $136.2 million (Q3 2025), and -$672.1 million (Q2 2025) per Business Quant data.